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OBJECTIVEdGlucose-dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1) have additive insulinotropic effects when coadministered in health. We aimed
to determine whether GIP confers additional glucose lowering to that of GLP-1 in the critically ill.
RESEARCH DESIGN AND METHODSdTwenty mechanically ventilated critically ill
patients without known diabetes were studied in a prospective, randomized, double-blind,
crossover fashion on 2 consecutive days. Between T0 and T420 minutes, GLP-1 (1.2 pmol/kg z
min21) was infused intravenously with either GIP (2 pmol/kg z min21) or 0.9% saline. Between
T60 and T420 minutes, nutrient liquid was infused into the small intestine at 1.5 kcal/min.
RESULTSdAdding GIP did not alter blood glucose or insulin responses to small intestinal
nutrient. GIP increased glucagon concentrations slightly before nutrient delivery (P5 0.03), but
not thereafter.
CONCLUSIONSdThe addition of GIP to GLP-1 does not result in additional glucose-lowering
or insulinotropic effects in critically ill patients with acute-onset hyperglycemia.
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Hyperglycemia occurs frequently inthe critically ill, even in the absenceof pre-existing diabetes (1). Al-
though insulin is an effective treatment,
its use confers an increased risk of hypo-
glycemia, which is associated with in-
creased mortality (1,2). In health, but not
in patients with type 2 diabetes, glucose-
dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
have additive insulinotropic effects when
coadministered, without increasing the
risk of hypoglycemia (3,4). The objective
of this study was to determine whether
the addition of GIP to GLP-1 would result
in additional glucose-lowering in enter-





Mechanically ventilated critically ill patients
were studied. Patientswith knowndiabetes,
HbA1c .6.5% (48 mmol/mol), previous
small intestinal surgery, or evidence of acute
or chronic pancreatitis were excluded.
Protocol
In this prospective, double-blind, cross-
over study performed on consecutive
days, patients were randomly assigned
to receive either the intervention (GIP at 2
pmol/kg zmin21) or control (intravenous
[IV] 0.9% saline) in addition to IV GLP-1
at 1.2 pmol/kg z min21. Patients were fasted
for 6 h, and exogenous insulin was
ceased 3 h prior to each study. Synthetic
GIP and GLP-1 (Bachem, Weil am Rhein,
Germany) were reconstituted in 0.9% sa-
line by the Royal Adelaide Hospital Phar-
macy, which undertook computer
generated randomization. The investiga-
tors remained blinded to treatment
allocation. Study solutions were adminis-
tered via low absorbance tubing. Between
T60 and T420, a mixed liquid nutrient (En-
sure Plus; Abbott Nutrition) was infused
into the small intestine at 1.5 kcal/min (5).
Arterial blood samples were obtained dur-
ing each study.
This study protocol was approved by
the Research Ethics Committee of the
Royal Adelaide Hospital with informed
consent obtained from patients’ next of
kin. The protocol was registered with
the Australian New Zealand Clinical Tri-
als Registry (ACTRN12611000735954).
Data analysis
Blood glucose concentrations were mea-
sured immediately using a blood gas
analyzer (ABL800 FLEX; Radiometer).
Serum insulin was measured by ELISA,
while plasma glucagon, GIP, and GLP-1
were measured using radioimmunoassays.
Statistical analysis
Based on previous data, 20 completed
subjects were required (5). Data are
presented as mean6 SD ormedian (range)
as appropriate. As data for inferential anal-
ysis were normally distributed, compari-
sons were made using the Student paired
t test. Because the islet cell effects of GIP are
glucose-dependent (6,7), the effect of GIP
in the subgroup of patients in whom peak
blood glucose concentrations were .10
mmol/L was also assessed.
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RESULTSdTwenty patients (age 52 6
16 years; sex: 12 male; HbA1c: 5.7%
[range 4.8–6.5%], 39 [29–48)] mmol/mol;
Acute Physiology and Chronic Health
Evaluation II score: 17 [9–30]; days in
ICUwhen studied: 6 [2–15] days; admis-
sion diagnostic group: sepsis, 9; trauma,
7; asthma, 2; neurological, 2) were
studied.
Blood glucose
Baseline blood glucose concentrations
were similar on both days (P 5 0.38). In
nine patients, the peak blood glucose was
.10 mmol/L at least on one study day.
GIP had no effect on fasting, peak,
or overall glycemic response in either
the entire cohort (Fig. 1A) or the group
with glycemic excursions .10 mmol/L
(Fig. 1B).
Insulin
Baseline insulin concentrations were simi-
lar on the 2 days (P 5 0.81). GIP had no
effect on fasting or overall insulin concen-
trations in either the entire cohort (Fig. 1C)
or the subgroup of patients with glycemic
excursions.10 mmol/L (P5 0.96).
Glucagon
Baseline glucagon concentrations were
similar on the 2 days (P5 0.48). The ad-
dition of GIP led to a minor increase in
glucagon before nutrient was given (T60:
152 6 93 vs. 145 6 113 pg/mL; P 5
0.03), but there was no difference at the
end of the infusion (P 5 0.55). Overall,
glucagon responses to the infusion were
also comparable regardless of GIP admin-
istration (Fig. 1D). There was no differ-
ence in the glucagon response between
the 2 days in patients with glycemic ex-
cursions .10 mmol/L (P 5 0.38).
GIP and GLP-1
Baseline GIP and GLP-1 concentrations
were similar on both days (P 5 0.79 and
0.35, respectively).While there was a sus-
tained twofold rise above fasting plasma
GIP concentrations in response to intra-
duodenal nutrient during the control in-
fusion (P , 0.001), GIP concentrations
were fourfold greater during GIP infusion
(P , 0.001). On both days, GLP-1 con-
centrations increased ;40% in response
to GLP-1 infusions, with the addition of
GIP having no effect on plasma GLP-1
concentrations (P 5 0.88).
CONCLUSIONSdThis study indi-
cates that IV administration of GIP to
Figure 1dEffects of the coinfusion of GIP and GLP-1 (open circles) when compared with GLP-1 alone (ﬁlled squares). A: Peak (P 5 0.43) and
overall glycemic response to nutrient infusion (P5 0.34) were similar. B: Overall glycemia in the subgroup (P5 0.55) of patients with excursions
.10 mmol/L was comparable (n5 9). C: Serum insulin concentrations were similar (P5 0.86). D: Overall plasma glucagon concentrations were
comparable (P5 0.39). Data are mean6 SD. Area under the curve calculated using the trapezoidal rule. Comparisons using paired Student t tests;
n 5 20 for all except the subgroup described.
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GLP-1 does not lower blood glucose
concentrations in the critically ill more
than exogenous GLP-1 alone. In keeping
with this, the addition of GIP does not
affect insulin or suppress glucagon re-
sponse to enteral nutrient. While these
observations are at variance with the out-
come of studies performed in healthy
volunteers (3,4), they are consistent
with the reported effects of concurrent
administration of GLP-1 and GIP in pa-
tients with type 2 diabetes (4,8).
The doses of GIP and GLP-1 used
were based on previous studies. We have
reported that GLP-1 at 1.2 pmol/kg z
min21 attenuates, but does not abolish,
the glycemic response to enteral nutrition
in critically ill patients with and without
type 2 diabetes (5,9,10). While this is the
ﬁrst report on the effects of GIP in the
critically ill, in healthy volunteers, the co-
infusion of GIP at doses .1 pmol/kg z
min21 is additive to the insulinotropic ef-
fect of GLP-1 (3,4). We conﬁrmed that
GIP concentrations reached pharmaco-
logical levels, so it appears unlikely that
the negative outcome of our study reﬂects
an insufﬁcient dose of GIP.
The reason GIP failed to lower glucose
concentrations may relate to antecedent
glycemic control, as the insulinotropic
effect of GIP is markedly attenuated
in various conditions associated with
chronic hyperglycemia, such as latent
autoimmune diabetes, chronic pancre-
atitis, and monogenic diabetes (11,12).
Moreover, in vivo, hyperglycemia acutely
reduces the expression of GIP receptors on
b-cells, providing a plausible explanation
as to why even pharmacological concen-
trations of GIP are not insulinotropic dur-
ing chronic hyperglycemia (13). Højberg
et al. (14) recently reported that the insu-
linotropic property of GIP increased several-
fold following 4 weeks of near-normal
glycemia in patients with type 2 diabe-
tes. These data and ours indicate that
the response of the b-cell to pharmaco-
logical doses of GIP is acutely suscepti-
ble to the effects of antecedent glycemia.
In both healthy humans and patients
with pre-existing hyperglycemia and
hyperglucagonemia, exogenousGIP is re-
portedly glucagonotropic, which would
counteract any insulinotropic effect
(6,8,11,15). However, we observed a
modest glucagontropic effect during fast-
ing (T60), which is unlikely to be of clinical
signiﬁcance.
There are limitations to our study.We
cannot exclude the possibility that GIP
alone lowers glycemia in the critically ill
compared with placebo. Our cohort was
relatively small and heterogeneous, and the
exposure to exogenous GIP was relatively
short (7 h). It therefore remains possible,
albeit intuitively unlikely, that an insulino-
tropic effect would be apparent during
more prolonged GIP exposure.
In conclusion, this study indicates
that the addition ofGIP to exogenousGLP-1
does not yield any additional glucose-
lowering effect, nor potentiate insulin
secretion, in critically ill patients. The
implication is that the insulinotropic
capacity of GIP, unlike GLP-1, is dimin-
ished in critically ill patients with hyper-
glycemia, as is the case in patients with
type 2 diabetes.
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